| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 05/08/2001 | US6228423 Biodegradable targetable microparticle delivery system |
| 05/08/2001 | US6228401 Processes for preparing flutamide compounds and compounds prepared by such processes |
| 05/08/2001 | US6228400 Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same |
| 05/08/2001 | US6228399 Cyclosporin, a phospholipid and at least one surface modifier, |
| 05/08/2001 | US6228398 Dosage form for increasing patient compliance by reducing dosage frequency; attention deficit disorder, methylphenidate or salts |
| 05/08/2001 | US6228397 Pharmaceutical composition having two coating layers |
| 05/08/2001 | US6228396 Injection moulded starch capsules with a coating of polymethyl methacrylate or copolymer of methacrylic acid and methyl methacrylate, |
| 05/08/2001 | US6228395 Sustained-release microgranules containing Diltiazem as the active principle |
| 05/08/2001 | US6228394 Supercritical fluid extraction of mould lubricant from hard shell capsules |
| 05/08/2001 | US6228393 Drug delivery via therapeutic hydrogels |
| 05/08/2001 | US6228391 Cationic lipid, |
| 05/08/2001 | US6228387 Integrated comprehensive hemorrhoid treatment compositions and regimen |
| 05/08/2001 | US6228383 Active substance and protective substance |
| 05/08/2001 | US6228381 Applying drugs for diagnosis |
| 05/08/2001 | US6228376 Adhesive cooling composition and process for its preparation |
| 05/08/2001 | US6228355 System for the control of enteropathogenic bacteria in the crops of poultry |
| 05/08/2001 | US6228354 Microbiocides for skin withh polyvinyl lactam and octylacrylamide, ph sensitive polymer methacrylate, neutralizer and alcohol |
| 05/08/2001 | US6228351 Medicated lip balm |
| 05/08/2001 | US6228348 Composition in the form of an oil-in-water emulsion comprising an acrylic terpolymer and its uses, in particular its cosmetic uses |
| 05/08/2001 | US6228347 Antioxidant gel for gingival conditions |
| 05/08/2001 | US6228346 Propellant mixtures and aerosols for micronizing medicaments with compressed gas |
| 05/08/2001 | US6228291 Process for preparing controlled-released chitosan microcapsule |
| 05/08/2001 | US6227195 Coarse spray delivery of functional biologic material |
| 05/08/2001 | CA2226166C Biocompatible and biodegradable nanoparticles designed for proteinaceous drugs absorption and delivery |
| 05/08/2001 | CA2144656C Antiperspirant-deodorant cosmetic stick products |
| 05/08/2001 | CA2122638C Formation of stable liposomes from lipid extracts of archaeobacteria (archaea) |
| 05/08/2001 | CA2097199C Preparation of prothrombin time reagents from recombinant human tissue factor and purified natural and synthetic phospholipids |
| 05/08/2001 | CA2065412C Methods of preventing and reducing the size of striae distensae lesions |
| 05/08/2001 | CA2047286C Feed additives for ruminants |
| 05/05/2001 | CA2293910A1 Segmented transdermal dosage unit |
| 05/03/2001 | WO2001031051A2 Antisense modulation of protein kinase c-theta expression |
| 05/03/2001 | WO2001030997A2 Microbe, microbial exopolysaccharide, and uses thereof |
| 05/03/2001 | WO2001030996A2 Microbial exopolysaccharide and uses thereof |
| 05/03/2001 | WO2001030843A1 Ligand activated transcriptional regulator proteins |
| 05/03/2001 | WO2001030804A2 Salt form of a conjugate useful in the treatment of prostate cancer |
| 05/03/2001 | WO2001030801A1 Antisense modulation of integrin-linked kinase expression |
| 05/03/2001 | WO2001030789A1 Ruthenium (ii) complexes with high antitumoral and antimetastatic activities |
| 05/03/2001 | WO2001030448A1 Method and compositions for administering taxanes orally to human patients |
| 05/03/2001 | WO2001030408A2 Adhesive composition over a bioactive polymerization initiator |
| 05/03/2001 | WO2001030395A1 Antisense modulation of tumor necrosis factor alpha converting enzyme (tace) expression |
| 05/03/2001 | WO2001030392A2 Delivery of proteins across polar epithelial cell layers |
| 05/03/2001 | WO2001030391A2 Pharmaceutical composition containing midazolam |
| 05/03/2001 | WO2001030386A1 Use of a cd40:cd154 binding interruptor to treat immunological complications of the eye |
| 05/03/2001 | WO2001030380A2 Methods and compositions for treatment of keratoconus using protease inhibitors |
| 05/03/2001 | WO2001030378A1 A method of prophylaxis and treatment |
| 05/03/2001 | WO2001030375A2 Use of gdnf for treating corneal defects |
| 05/03/2001 | WO2001030372A2 Pharmaceutical agent preparations |
| 05/03/2001 | WO2001030366A2 Use of parvoviruses for improving the general condition of tumour patients or patients having chronic or consumptive diseases |
| 05/03/2001 | WO2001030362A2 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 05/03/2001 | WO2001030358A1 Contraceptive medicament based on a progesterone and an oestrogen and method for producing the same |
| 05/03/2001 | WO2001030355A1 Contraceptive medicine based on a progestational agent and an oestrogen and preparation method |
| 05/03/2001 | WO2001030351A1 Oral formulations for anti-tumor compounds |
| 05/03/2001 | WO2001030349A1 Amorphous paroxetine compositon |
| 05/03/2001 | WO2001030345A1 Clonidine preparations |
| 05/03/2001 | WO2001030337A2 Ophthalmic formulation of dopamine antagonists |
| 05/03/2001 | WO2001030336A2 Pharmaceutical formulations comprising resveratrol and use thereof |
| 05/03/2001 | WO2001030323A2 Controlled-release biocompatible ocular drug delivery implant devices and methods |
| 05/03/2001 | WO2001030322A1 Swellable delivery system |
| 05/03/2001 | WO2001030321A1 Oral dosage form comprising a salt of morphine or a morphine derivative |
| 05/03/2001 | WO2001030320A1 Biodegradable microparticles with novel erythropoietin stimulating protein |
| 05/03/2001 | WO2001030319A1 New and improved formulation for paclitaxel |
| 05/03/2001 | WO2001030318A1 Oral solution containing galanthamine and a sweetening agent |
| 05/03/2001 | WO2001030317A1 Treatment and prevention of herpes simplex infections |
| 05/03/2001 | WO2001030316A2 Transdermal drug delivery devices comprising (r)-(z)-1-azabicyclo(2.2.1)heptan-3-one, 0-(3(3-methoxyphenyl)-2-propynyl)oxime |
| 05/03/2001 | WO2001030288A1 Oral transmucosal drug dosage using solid solution |
| 05/03/2001 | WO2001030287A1 Local prevention or amelioration of pain from surgically closed wounds |
| 05/03/2001 | WO2001030263A1 Medication retention assembly for oral delivery tray |
| 05/03/2001 | WO2001030146A1 Encapsulated active material immobilized in hydrogel microbeads |
| 05/03/2001 | WO2001030145A1 Active material within hydrogel microbeads |
| 05/03/2001 | WO2001013893A3 Use of simple amino acids to form porous particles |
| 05/03/2001 | WO2001003917A3 Multilayered film containing an active substance and made of cross-linked hydrophilic polymers |
| 05/03/2001 | WO2001001139A3 Incorporation and appliations of biomolecular interactions within a carrier |
| 05/03/2001 | WO2001000221A3 Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
| 05/03/2001 | WO2000071096A3 Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases |
| 05/03/2001 | WO2000066107A3 Antimalarian agents for the treatment of asthma |
| 05/03/2001 | WO2000004875A3 Preparation of aqueous clear solution dosage forms with bile acids |
| 05/03/2001 | WO1999059544A3 Orally disintegrable tablets |
| 05/03/2001 | US20010000802 Implantable system with drug-eluting cells for on-demand local drug delivery |
| 05/03/2001 | US20010000785 Attaching a bioeffecting agent to a substrate with an anchor provided by a linker compound which also forms a cleavable linkage so that the drug has a sustained release; anti-thrombogenic, -imicrobial, -inflammatory agents |
| 05/03/2001 | US20010000729 Container for an inhalation anesthetic |
| 05/03/2001 | US20010000728 A compliant poly(ethylene glycol)-oligotrimethylene carbonate copolymer on a tissue surface, wherein the normalized compliance ratio of the tissue and the material is about 0.5 to 3 |
| 05/03/2001 | DE19951617A1 Zubereitungen pharmazeutische Wirkstoffe Preparations active pharmaceutical ingredients |
| 05/03/2001 | DE19949202A1 Transdermales therapeutisches System zur Abgabe von Acetylsalicylsäure und/oder Salicylsäure Transdermal therapeutic system for the delivery of acetylsalicylic acid and / or salicylic acid |
| 05/03/2001 | DE10038203A1 Implantable active agent depot, useful e.g. in local tumor treatment or gene therapy, comprising drug-containing, cubic phase forming lipid matrix containing modifier molecule to control release kinetics |
| 05/03/2001 | CA2389583A1 Method and compositions for administering taxanes orally to human patients |
| 05/03/2001 | CA2389171A1 Ruthenium (ii) complexes with high antitumoral and antimetastatic activities |
| 05/03/2001 | CA2388924A1 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 05/03/2001 | CA2388724A1 Oral glutamine in the prevention of neonatal necrotizing enterocolitis and other gastrointestinal mucosal damage |
| 05/03/2001 | CA2388614A1 Pharmaceutical agent preparations |
| 05/03/2001 | CA2388613A1 New and improved formulation for paclitaxel |
| 05/03/2001 | CA2388611A1 Transdermal drug delivery devices |
| 05/03/2001 | CA2388535A1 Ligand activated transcriptional regulator proteins |
| 05/03/2001 | CA2388203A1 Microbe, microbial exopolysaccharide, and uses thereof |
| 05/03/2001 | CA2388123A1 Oral dosage form comprising a salt of morphine or a morphine derivative |
| 05/03/2001 | CA2387901A1 Salt form of a conjugate useful in the treatment of prostate cancer |
| 05/03/2001 | CA2387889A1 Use of a cd40:cd154 binding interruptor to treat immunological complications of the eye |
| 05/03/2001 | CA2387652A1 A method of prophylaxis and treatment |
| 05/03/2001 | CA2387648A1 Oral formulations for anti-tumor compounds |
| 05/03/2001 | CA2387229A1 Biodegradable microparticles with novel erythropoietin stimulating protein |
| 05/03/2001 | CA2387209A1 Active material within hydrogel microbeads |